<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949688</url>
  </required_header>
  <id_info>
    <org_study_id>SUMS-22-15</org_study_id>
    <secondary_id>22-15</secondary_id>
    <nct_id>NCT01949688</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors</brief_title>
  <official_title>Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 or HLA-A*02 in Patients With Advanced Solid Tumors That Are Refractory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiga University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shiga University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators examine using a combination of two types of HLA-A*2402 (or&#xD;
      HLA-A*0201)-restricted epitope peptides, which were derived from VEGF-R1 and VEGF-R2 the&#xD;
      safety, immunogenicity, and antitumor effect of vaccine treatment for advanced solid tumor&#xD;
      patients who are refractory to standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, immune response and&#xD;
      clinical efficacies of HLA-A*2402 or HLA-A*0201 restricted epitope peptides (VEGF-R1 and&#xD;
      VEGF-R2) emulsified with Montanide ISA 51 for advanced solid tumors.&#xD;
&#xD;
      In this phase I/II trial, the investigators examine using a combination of the two peptides&#xD;
      the safety, immunogenicity, and antitumor effect of vaccine treatment for HLA-A*2402 or&#xD;
      HLA-A*0201-positive advanced solid tumor patients who are refractory to standard therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety: the number of adverse events of vaccination therapy.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of clinical efficacy: Overall survival.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Various immunological responses including peptides specific CTL, antigen cascade, regulatory T cells, cancer antigens and HLA levels.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical efficacy: Progression free survival.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical efficacy: Tumor markers.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical efficacy: Objective response rate.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>HLA-A*2402 restricted peptides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-A*2402 restricted peptides with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLA-A*0201 restricted peptides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-A*0201 restricted peptides with adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HLA-A*2402 or A*0201 restricted peptides</intervention_name>
    <description>Open Label, Non-Randomized, Safety/Efficacy study:&#xD;
HLA-A*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.&#xD;
HLA-A*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.</description>
    <arm_group_label>HLA-A*0201 restricted peptides</arm_group_label>
    <arm_group_label>HLA-A*2402 restricted peptides</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Advanced solid tumors that are refractory to standard therapies or that cannot be&#xD;
             treated with those due to medical reason.&#xD;
&#xD;
          2. ECOG performance status 0-1&#xD;
&#xD;
          3. Age between 20 to 85&#xD;
&#xD;
          4. Clinical efficacy can be evaluated by some methods&#xD;
&#xD;
          5. No prior chemotherapy, radiation therapy, hyperthermia or immunotherapy within two&#xD;
             weeks&#xD;
&#xD;
          6. Life expectancy &gt; 3 months&#xD;
&#xD;
          7. Laboratory values as follows 1500/mm3 &lt; WBC &lt; 10000/mm3 Platelet count &gt; 75000/mm3 15%&#xD;
             &lt; Lymphcyte fraction Asparate transaminase &lt; 3 X cutoff value Alanine transaminase &lt; 3&#xD;
             X cutoff value Total bilirubin &lt; 3 X cutoff value Serum creatinine &lt; 2X cutoff value&#xD;
&#xD;
          8. HLA-A*2402 or HLA-A*0201&#xD;
&#xD;
          9. Able and willing to give valid written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active and uncontrolled cardiac disease (i.e. coronary syndromes, arrhythmia)&#xD;
&#xD;
          2. Myocardial infarction within six months before entry&#xD;
&#xD;
          3. Breastfeeding and Pregnancy (woman of child bearing potential)&#xD;
&#xD;
          4. Active and uncontrolled infectious disease&#xD;
&#xD;
          5. Concurrent treatment with steroids or immunosuppressing agent&#xD;
&#xD;
          6. Other malignancy requiring treatment&#xD;
&#xD;
          7. Non-cured traumatic wound&#xD;
&#xD;
          8. Decision of unsuitableness by principal investigator or physician-in-charge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yataro Daigo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiga University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Ohtsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <last_update_submitted>March 15, 2019</last_update_submitted>
  <last_update_submitted_qc>March 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiga University</investigator_affiliation>
    <investigator_full_name>Yataro Daigo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

